Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Sponsor
Actavis Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT02512042
Collaborator
(none)
973
10
2
13
97.3
7.5

Study Details

Study Description

Brief Summary

This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% ophthalmic suspension of Alcon Laboratories, Inc. in the treatment of chronic open angle glaucoma or ocular hypertension in both eyes.

Condition or Disease Intervention/Treatment Phase
  • Drug: Test-Brinzolamide 1% Ophthalmic suspension
  • Drug: Reference-Brinzolamide 1% Ophthalmic suspension
Phase 3

Detailed Description

Study will be conducted in adult subjects, above 18 years inclusive, males and non pregnant females, diagnosed with chronic open angle glaucoma or ocular hypertension in both eyes. Qualifying Intra Ocular Pressure (IOPs) following wash-out, at baseline (Day 0/hour 0 i.e., 8:00 am) should be ≥ 22 milli meter mercury (mm Hg) and ≤ 34 mm Hg in each eye and any asymmetry of IOP between the eyes no greater than 5 mm Hg.

Each study subject will use one drop of test or reference Ophthalmic Suspension in both the eyes three times daily at approximately 8:00am, 04:00 pm and 10:00 pm for 42 days (6 weeks). The dose and mode of treatment chosen in this study is the dosage approved by United States Food and Drug administration (US FDA) for use in treatment of patients of Chronic Open Angle Glaucoma.

The study subjects will undergo clinical evaluations throughout the study in order to assess efficacy and safety. Study subject primary endpoint evaluation will be assessed after 2 weeks (14 days) and 6 weeks (42 days) of treatment for each study subject deemed eligible for evaluation, (i.e., at Visit III - Day 14 ± 2 days and Visit IV - Day 42 ± 3 days).

The primary bioequivalence comparison is between the test and reference products for the mean difference in intraocular pressure (IOP) of both eyes at four time points, i.e., at approximately 8:00 am and 10:00 am at the Day 14 (± 2 days) and Day 42 (± 3 days) visits.

Study Design

Study Type:
Interventional
Actual Enrollment :
973 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
A Multicentre, Double Blind, Active Controlled, Parallel Group, Two Arm, Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% Ophthalmic Suspension of Alcon Laboratories, Inc., In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
Actual Study Start Date :
Apr 1, 2015
Actual Primary Completion Date :
Apr 1, 2016
Actual Study Completion Date :
May 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Brinzolamide 1% Ophthalmic suspension

Brinzolamide Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Indoco Remedies, Ltd for Watson Pharma Pvt. Ltd

Drug: Test-Brinzolamide 1% Ophthalmic suspension

Active Comparator: Azopt® 1% Ophthalmic suspension

Azopt® (Contains Brinzolamide) Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Alcon Laboratories, Inc

Drug: Reference-Brinzolamide 1% Ophthalmic suspension

Outcome Measures

Primary Outcome Measures

  1. Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time Points [Day 14 and 42 at 8AM and 10AM]

    The primary efficacy end point is the mean difference in intraocular pressure (IOP) of both eyes between the two treatment groups at four time points, i.e., at approximately 8:00 am (hour 0; before the morning drop) and 10:00 am (hour 2; after the morning drop) at the Day 14 (week 2) and Day 42 (week 6) visits

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Male or non-pregnant females aged 18 years and above with a Body Mass Index (BMI) of 18.5 to 35 Kg/m2, with chronic open angle glaucoma or ocular hypertension in both eyes on stable ocular hypotensive treatment regimen.

  2. Subjects requiring treatment of both eyes and are able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.

  3. Adequate wash-out period prior to baseline of any ocular hypotensive medication. In order to minimize potential risk to subjects due to IOP elevations during the washout period, investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandins. However, subjects must have discontinued all ocular hypotensive medication for the minimum washout period.

  4. Baseline (Day 0/hour 0) IOP ≥ 22 mm Hg and ≤ 34 mm Hg in each eye and any asymmetry of IOP between the eyes no greater than 5 mm Hg.

  5. Baseline best corrected visual acuity equivalent to 20/200 or better in each eye.

  6. Study subjects must have provided IRB approved written informed consent using the latest version of the IRB informed consent form. In addition, study subjects must sign a Health Insurance Portability and Accountability Act (HIPAA) authorization, if applicable.

  7. Study subjects should be literate and willing to complete the subject diary regularly as directed.

  8. Study subjects must be in good health and free from any clinically significant disease apart from indication under study.

  9. Females of child bearing potential (WOCBP*) must not be pregnant or lactating at baseline visit (as documented by a negative serum pregnancy test with a minimum sensitivity of 25 IU/L or equivalent units of beta-human chorionic gonadotropin (Beta-HCG) at screening and urine pregnancy at baseline.

*All female subjects will be considered to be of childbearing potential unless they are postmenopausal. Female subjects of childbearing potential (WOCBP) are defined as sexually mature women without prior hysterectomy, or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for the past 12 or more months are still considered to be of childbearing potential, if the amenorrhea is possibly due to other causes, including prior chemotherapy, anti-estrogens, or ovarian suppression. Postmenopausal women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or women who have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy with surgery at least 4 weeks prior to randomization) are not considered WOCBP. Subjects who have undergone tubal ligation are NOT considered as surgically sterile.

  1. Female subjects of childbearing potential must be willing to use an acceptable form of birth control from the day of the first dose administration to 30 days after the last administration of IP. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (Medroxyprogesterone acetate- stabilized for at least 3 months); vaginal contraceptive; contraceptive implant; double barrier methods (e.g. condom and spermicide); Nuvaring vaginal hormonal birth control, IUD, or abstinence with a second method of birth control should the subject become sexually active. A sterile sexual partner is NOT considered an adequate form of birth control.

  2. All male subjects must agree to use accepted methods of birth control with their partners, from the day of the first dose administration (to 30 days after the last administration of study drug). Please see acceptable forms for "Female" birth control above. Abstinence is an acceptable method of birth control for males.

  3. Study subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required scheduled study visits.

  4. Study subjects must be willing to refrain from using any other treatments for Chronic Open Angle Glaucoma (COAG), other than the investigational product.

Exclusion Criteria:
  1. Females who are pregnant, breast feeding, or planning a pregnancy during the course of the study and for 30 days after last study dose.

  2. Females of childbearing potential who do not agree to utilize an adequate form of contraception.

  3. Current or past history of severe hepatic or renal impairment.

  4. Current or history within two months prior to baseline of significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye.

  5. Current corneal abnormalities that would prevent accurate IOP readings with the Goldmann applanation tonometer e.g. corneal dystrophy, corneal abrasions, corneal ulcers, keratitis, keratoconus and keratoglobus.

  6. Functionally significant visual field loss

  7. Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to any component of brinzolamide or sulfonamide therapy

  8. Use at any time prior to baseline of intraocular corticosteroid implant.

  9. Use within one week prior to baseline of contact lens

  10. Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, or 2) topical corticosteroid

  11. Use within one month prior to baseline of: 1) systemic corticosteroid or 2) high-dose salicylate therapy defined as 325mg taken on three consecutive days.

  12. Use within six months prior to baseline of intravitreal or subtenon injection of ophthalmic corticosteroid

  13. Underwent within six months prior to baseline any other intraocular surgery (e.g., cataract surgery)

  14. Underwent within twelve months prior to baseline: refractive surgery, filtering surgery or laser surgery for IOP reduction

  15. Amblyopia - only one sighted eye

  16. Severe retinal disease or other severe ocular pathology, such as glaucomatous damage with a cup/disc ratio greater than 0.8, split fixation, or functionally significant (in the investigators' opinion) visual field loss

  17. History or presence of significant alcoholism or drug abuse in the past one year

  18. History or presence of significant smoking (more than 20 cigarettes or any other equivalent tobacco product/day)

  19. History of hematologic disorders other than mild anemia

  20. Severe, unstable, or uncontrolled cardiovascular or pulmonary disease

  21. Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg, Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg and Pulse rate less than 50 beats/minute or more than 100 beats/minute

  22. Any form of glaucoma other than chronic open-angle glaucoma

  23. Therapy with an investigational agent within the past 30 days

  24. Clinically significant hematologic and / or biochemical abnormalities based on laboratory testing

  25. Subjects who are in the investigator's best judgment at risk of visual field or visual acuity worsening as a consequence of participation of trial.

  26. Chronic use of any systemic medication that may affect IOP with less than three month stable dosing regimen (i.e., sympathomimetic agents, beta-adrenergic blocking agents, alpha agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin -converting enzyme inhibitors, etc.)

  27. Use of any prescribed medication during last two weeks or Over the Counter (OTC) medicinal products during the last one week preceding the first dosing that is affecting the IOP or result in drug-drug interaction with the study drug.

  28. Major illness, as per investigator discretion, during 3 months before screening

  29. Subjects who are employees of site or Clinical research organization (CRO) or sponsor or immediate family of employees

  30. Participating in a clinical study within the past 3 months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 David Wirta, MD Newport Beach California United States 92663
2 Shettle Eye Research, Inc. Largo Florida United States 33773
3 AMB Research Center, Inc. Miami Florida United States 33144
4 Eye Care Centers Management, Inc. Morrow Georgia United States 30260
5 Coastal Research Associates, LLC Roswell Georgia United States 30076
6 Heart of America Eye Care PA Shawnee Mission Kansas United States 66204
7 Ophthalmology Associates Saint Louis Missouri United States 63131
8 Las Vegas Physicians Research Group Henderson Nevada United States 89074
9 Keystone Research Ltd. Austin Texas United States 78731
10 Keystone Research Ltd. San Antonio Texas United States 78240

Sponsors and Collaborators

  • Actavis Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Actavis Inc.
ClinicalTrials.gov Identifier:
NCT02512042
Other Study ID Numbers:
  • WAT/BNZL/2014
First Posted:
Jul 30, 2015
Last Update Posted:
Mar 2, 2020
Last Verified:
Feb 1, 2020

Study Results

Participant Flow

Recruitment Details
Pre-assignment Detail The populations for this study included the Randomized Population, Safety Population and Per Protocol Population.
Arm/Group Title Generic Brinzolamide Ophthalmic Suspension USP 1% Azopt® (Brinzolomide Ophthalmic Suspension USP 1%)
Arm/Group Description Study subjects used one drop in both eyes three times daily for 42 days. Study subjects used one drop in both eyes three times daily for 42 days.
Period Title: Overall Study
STARTED 495 478
COMPLETED 472 453
NOT COMPLETED 23 25

Baseline Characteristics

Arm/Group Title Generic Brinzolamide 1% Ophthalmic Suspension Azopt® 1% Ophthalmic Suspension Total
Arm/Group Description Study subjects used one drop in both eyes three times daily for 42 days. Study subjects used one drop in both eyes three times daily for 42 days. Total of all reporting groups
Overall Participants 495 478 973
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]
52.8
(14.50)
53.0
(14.19)
52.9
(14.34)
Sex: Female, Male (Count of Participants)
Female
222
44.8%
206
43.1%
428
44%
Male
273
55.2%
272
56.9%
545
56%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino
16
3.2%
20
4.2%
36
3.7%
Not Hispanic or Latino
431
87.1%
417
87.2%
848
87.2%
Unknown or Not Reported
48
9.7%
41
8.6%
89
9.1%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native
0
0%
0
0%
0
0%
Asian
414
83.6%
402
84.1%
816
83.9%
Native Hawaiian or Other Pacific Islander
0
0%
0
0%
0
0%
Black or African American
14
2.8%
13
2.7%
27
2.8%
White
67
13.5%
61
12.8%
128
13.2%
More than one race
0
0%
0
0%
0
0%
Unknown or Not Reported
0
0%
2
0.4%
2
0.2%
Iris Colour (Count of Participants)
Blue
18
3.6%
16
3.3%
34
3.5%
Green
7
1.4%
7
1.5%
14
1.4%
Grey
21
4.2%
31
6.5%
52
5.3%
Hazel
15
3%
10
2.1%
25
2.6%
Brown
282
57%
265
55.4%
547
56.2%
Black
152
30.7%
149
31.2%
301
30.9%

Outcome Measures

1. Primary Outcome
Title Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time Points
Description The primary efficacy end point is the mean difference in intraocular pressure (IOP) of both eyes between the two treatment groups at four time points, i.e., at approximately 8:00 am (hour 0; before the morning drop) and 10:00 am (hour 2; after the morning drop) at the Day 14 (week 2) and Day 42 (week 6) visits
Time Frame Day 14 and 42 at 8AM and 10AM

Outcome Measure Data

Analysis Population Description
Participants in Per Protocol Population who met inclusion/exclusion criteria, instilled a pre-specified proportion of the scheduled doses for the specified duration of the study, who did not miss scheduled applications for more than 3 days, and completed evaluations at Day 14 and Day 42 within the visit window.
Arm/Group Title Generic Brinzolamide Ophthalmic Suspension USP 1% Azopt® (Brinzolomide Ophthalmic Suspension USP 1%)
Arm/Group Description Study subjects used one drop in both eyes three times daily for 42 days. Study subjects used one drop in both eyes three times daily for 42 days.
Measure Participants 489 475
8AM Visit Day 14
19.35
(2.860)
19.75
(2.874)
8AM Visit Day 42
18.53
(2.894)
18.66
(2.851)
10AM Visit Day 14
18.70
(2.805)
19.18
(2.710)
10AM Visit Day 42
17.94
(2.734)
18.16
(2.824)
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Generic Brinzolamide Ophthalmic Suspension USP 1%, Azopt® (Brinzolomide Ophthalmic Suspension USP 1%)
Comments
Type of Statistical Test Equivalence
Comments The limits of each two-sided 95% confidence interval of the treatment difference (test-reference) for mean IOP of both eyes at approximately 8:00 (hours 0, before the morning drop) at the Day 14 visit should be within +/-1.5mm Hg, and should be within +/-1.0mm Hg for majority of time points using the PP population.
Statistical Test of Hypothesis p-Value
Comments
Method
Comments
Method of Estimation Estimation Parameter Mean Difference (Net)
Estimated Value -0.36
Confidence Interval (2-Sided) 95%
-0.69 to -0.03
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection Generic Brinzolamide Ophthalmic Suspension USP 1%, Azopt® (Brinzolomide Ophthalmic Suspension USP 1%)
Comments
Type of Statistical Test Equivalence
Comments The limits of each two-sided 95% confidence interval of the treatment difference (test-reference) for mean IOP of both eyes at approximately 8:00 hour on Day 42 should be within +/-1.5mm Hg, and should be within +/- 1.0mm Hg for majority of time points using the PP population.
Statistical Test of Hypothesis p-Value
Comments
Method
Comments
Method of Estimation Estimation Parameter Mean Difference (Net)
Estimated Value -0.11
Confidence Interval (2-Sided) 95%
-0.43 to 0.22
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 3
Statistical Analysis Overview Comparison Group Selection Generic Brinzolamide Ophthalmic Suspension USP 1%, Azopt® (Brinzolomide Ophthalmic Suspension USP 1%)
Comments
Type of Statistical Test Equivalence
Comments The limits of each two-sided 95% confidence interval of the treatment difference (test-reference) for mean IOP of both eyes at approximately 10:00 hour on Day 14 should be within +/-1.5mm Hg, and should be within +/-1.0mm Hg for majority of time points using the PP population.
Statistical Test of Hypothesis p-Value
Comments
Method
Comments
Method of Estimation Estimation Parameter Mean Difference (Net)
Estimated Value -0.40
Confidence Interval (2-Sided) 95%
-0.71 to -0.09
Parameter Dispersion Type:
Value:
Estimation Comments
Statistical Analysis 4
Statistical Analysis Overview Comparison Group Selection Generic Brinzolamide Ophthalmic Suspension USP 1%, Azopt® (Brinzolomide Ophthalmic Suspension USP 1%)
Comments
Type of Statistical Test Equivalence
Comments The limits of each two-sided 95% confidence interval of the treatment difference (test-reference) for mean IOP of both eyes at approximately 10:00 hour on Day 42 should be within +/-1.5mm Hg, and should be within +/-1.0mm Hg for majority of time points using the PP population
Statistical Test of Hypothesis p-Value
Comments
Method
Comments
Method of Estimation Estimation Parameter Mean Difference (Net)
Estimated Value -0.19
Confidence Interval (2-Sided) 95%
-0.50 to 0.13
Parameter Dispersion Type:
Value:
Estimation Comments

Adverse Events

Time Frame Baseline up to 45 days
Adverse Event Reporting Description Adverse events were collected from participants who were randomized and received the study drug.
Arm/Group Title Generic Brinzolamide 1% Ophthalmic Suspension Azopt® 1% Ophthalmic Suspension
Arm/Group Description Study subjects used one drop in both eyes three times daily for 42 days. Study subjects used one drop in both eyes three times daily for 42 days.
All Cause Mortality
Generic Brinzolamide 1% Ophthalmic Suspension Azopt® 1% Ophthalmic Suspension
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total / (NaN) / (NaN)
Serious Adverse Events
Generic Brinzolamide 1% Ophthalmic Suspension Azopt® 1% Ophthalmic Suspension
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/489 (0%) 0/475 (0%)
Other (Not Including Serious) Adverse Events
Generic Brinzolamide 1% Ophthalmic Suspension Azopt® 1% Ophthalmic Suspension
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 55/489 (11.2%) 57/475 (12%)
Cardiac disorders
Palpitations 1/489 (0.2%) 1 0/475 (0%) 0
Sinus bradycardia 1/489 (0.2%) 1 0/475 (0%) 0
Eye disorders
Asthenopia 1/489 (0.2%) 1 1/475 (0.2%) 1
Blepharospasm 0/489 (0%) 0 1/475 (0.2%) 1
Cataract nuclear 1/489 (0.2%) 1 0/475 (0%) 0
Chalazion 1/489 (0.2%) 1 0/475 (0%) 0
Conjunctival disorder 0/489 (0%) 0 1/475 (0.2%) 1
Conjunctival haemorrhage 1/489 (0.2%) 1 0/475 (0%) 0
Conjunctival hyperaemia 1/489 (0.2%) 1 1/475 (0.2%) 1
Dry eye 5/489 (1%) 5 2/475 (0.4%) 2
Excessive eye blinking 0/489 (0%) 0 1/475 (0.2%) 1
Eye discharge 1/489 (0.2%) 1 0/475 (0%) 0
Eye inflammation 0/489 (0%) 0 2/475 (0.4%) 2
Eye irritation 20/489 (4.1%) 21 7/475 (1.5%) 7
Eye pain 4/489 (0.8%) 4 5/475 (1.1%) 5
Eye pruritus 3/489 (0.6%) 4 1/475 (0.2%) 2
Eyelid dermatochalasis 0/489 (0%) 0 1/475 (0.2%) 1
Eyelid irritation 0/489 (0%) 0 1/475 (0.2%) 1
Eyelid margin crusting 0/489 (0%) 0 3/475 (0.6%) 3
Foreign body sensation in eyes 1/489 (0.2%) 1 1/475 (0.2%) 1
Keratitis 0/489 (0%) 0 1/475 (0.2%) 1
Lacrimation increased 3/489 (0.6%) 3 3/475 (0.6%) 3
Ocular hyperaemia 5/489 (1%) 6 3/475 (0.6%) 3
Photophobia 0/489 (0%) 0 1/475 (0.2%) 1
Punctuate keratitis 1/489 (0.2%) 2 1/475 (0.2%) 1
Vision blurred 6/489 (1.2%) 6 12/475 (2.5%) 14
Visual acuity reduced 1/489 (0.2%) 1 0/475 (0%) 0
Gastrointestinal disorders
Abdominal discomfort 1/489 (0.2%) 1 0/475 (0%) 0
Diarrhoea 2/489 (0.4%) 2 0/475 (0%) 0
Dry mouth 1/489 (0.2%) 1 0/475 (0%) 0
Gastrooesophageal reflux disease 1/489 (0.2%) 1 0/475 (0%) 0
Hyperchlorhydria 0/489 (0%) 0 1/475 (0.2%) 1
Nausea 1/489 (0.2%) 1 0/475 (0%) 0
Oral discomfort 0/489 (0%) 0 1/475 (0.2%) 1
Stomatitis 0/489 (0%) 0 1/475 (0.2%) 1
Toothache 0/489 (0%) 0 2/475 (0.4%) 2
General disorders
Asthenia 1/489 (0.2%) 2 0/475 (0%) 0
Face oedema 0/489 (0%) 0 1/475 (0.2%) 1
Oedema peripheral 0/489 (0%) 0 1/475 (0.2%) 1
Pyrexia 3/489 (0.6%) 3 3/475 (0.6%) 3
Infections and infestations
Diverticulitis 1/489 (0.2%) 1 0/475 (0%) 0
Influenza 0/489 (0%) 0 1/475 (0.2%) 1
Lower respiratory tract infection 0/489 (0%) 0 1/475 (0.2%) 1
Nasopharyngitic 1/489 (0.2%) 1 2/475 (0.4%) 2
Sinusitis 0/489 (0%) 0 2/475 (0.4%) 2
Upper respiratory tract infection 0/489 (0%) 0 1/475 (0.2%) 1
Viral infection 0/489 (0%) 0 1/475 (0.2%) 1
Injury, poisoning and procedural complications
Muscle strain 0/489 (0%) 0 1/475 (0.2%) 1
Investigations
Hepatic enzyme increased 0/489 (0%) 0 1/475 (0.2%) 1
Mycobacterium tuberculosis complex test positive 0/489 (0%) 0 1/475 (0.2%) 1
Vital dye staining cornea present 0/489 (0%) 0 1/475 (0.2%) 1
Musculoskeletal and connective tissue disorders
Arthralgia 0/489 (0%) 0 1/475 (0.2%) 1
Back pain 1/489 (0.2%) 1 0/475 (0%) 0
Nervous system disorders
Dysgeusia 5/489 (1%) 5 2/475 (0.4%) 2
Headache 3/489 (0.6%) 6 9/475 (1.9%) 10
Migraine 0/489 (0%) 0 1/475 (0.2%) 1
Psychiatric disorders
Anxiety 1/489 (0.2%) 1 0/475 (0%) 0
Renal and urinary disorders
Nephrolithiasis 1/489 (0.2%) 1 0/475 (0%) 0
Respiratory, thoracic and mediastinal disorders
Cough 0/489 (0%) 0 2/475 (0.4%) 2
Hiccups 1/489 (0.2%) 1 0/475 (0%) 0
Oropharyngeal pain 2/489 (0.4%) 2 0/475 (0%) 0
Rhinitis allergic 1/489 (0.2%) 1 0/475 (0%) 0
Throat irritation 0/489 (0%) 0 1/475 (0.2%) 1
Skin and subcutaneous tissue disorders
Dermatitis contact 1/489 (0.2%) 1 0/475 (0%) 0
Rash 1/489 (0.2%) 1 0/475 (0%) 0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.

Results Point of Contact

Name/Title Director, CE Studies
Organization Teva Pharmaceuticals USA, Inc.
Phone 1-888-483-8279
Email USMedinfo@tevapharm.com
Responsible Party:
Actavis Inc.
ClinicalTrials.gov Identifier:
NCT02512042
Other Study ID Numbers:
  • WAT/BNZL/2014
First Posted:
Jul 30, 2015
Last Update Posted:
Mar 2, 2020
Last Verified:
Feb 1, 2020